Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015 by Julian, Halcox
1 
 
Temporal trends in the incidence, treatment patterns, and outcomes of coronary 
artery disease and peripheral artery disease in the United Kingdom, 2006-2015  
Varun Sundaram MD, FRCP 1, 2, Chloe Bloom MBChB, Ph.D. 2, Rosita Zakeri MBChB, Ph.D. 2 ,3, Prof 
Julian Halcox MD 4,  Alexander Cohen MD8, Kevin Bowrin Msc 6, Jean-Baptiste-Briere PharmD7, 
Amitava Banerjee MBChB, D.Phil 5,  Prof Daniel I. Simon MD, FAHA 1,  Prof John GF Cleland MD, 
FRCP 2,9,  Prof Sanjay Rajagopalan MD, FAHA 2, Jennifer K. Quint MBChB, Ph.D 2,10 
1. Department of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University 
Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA  
2. Department of Population Health, National Heart and Lung Institute, Imperial College London, 
London, UK 
3. Department of Cardiovascular Medicine, Royal Brompton and Harefield Hospitals NHS Foundation 
Trust, London, UK 
4. Department of Cardiovascular Medicine, Swansea University Medical School, UK  
5. Department of Hematological Medicine, Guy's & St Thomas' NHS Foundation Trust, King's College 
London, Westminster Bridge Road, London, UK. 
6. Bayer plc, Reading UK. 
7. Bayer AG, Berlin, Germany 
8. Institute of Health Informatics, University College London, London, UK  
9. Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow  
10. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, 
London, UK 
 













Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Centre, Case 
Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, Ohio, 44106, USA; 
Emmanuel Kaye Building, Manresa Road, National Heart and Lung Institute, Imperial College, 
London, SW3 6LR, UK 
Tel: +12168447690; +44 (0) 207 594 882; Fax; +12168448954 






For the past four decades, high-income countries have experienced a tremendous decline in the 
standardised incidence rates of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular 
(CV) mortality.1–5  Nevertheless, ASCVD remains one of the leading causes of death and disability-
adjusted life-years.1,6 The age standardised prevalence of CAD in the in the UK and Europe in 2015 
has been reported to be 2.5 % and 3.7% respectively. 6 The clinical spectrum of ASCVD is wide and 
can be broadly categorised into those involving the coronary arteries (CAD), other vascular beds 
(e.g., peripheral arterial disease-PAD) or both.7,8 Estimating the population level incidence of ASCVD 
stratified by the involvement of vascular beds may help inform health policy, as resource utilisation 
and economic burden related to management may be influenced by the type of vascular beds 
involved.9,10 
Most studies estimating the incidence of CAD have included either chronic ischemic heart disease 
from general practice (GP) consultations or acute myocardial infarction (AMI) from hospital 
admissions. 1,11–13 Previous studies have shown that failure to use linked primary and secondary care 
data can lead to a substantial (25-50%) underestimate of the burden of CAD.14 Therefore, analyses of 
clinical encounters across the entire spectrum of health care services (both inpatient and outpatient) 
are required to capture the full burden of CAD.  
Peripheral arterial disease (PAD) is reported to affect about 13% of people aged greater than 50 
years in Western Europe and North America.7,15 In spite of its high prevalence and poor prognosis, 
PAD attracts less attention in terms of research, early detection, and treatment. 16,17 There is a 
paucity of PAD data in terms of geographic and secular trends in the incidence, patient 
characteristics, treatment patterns, and survival. 
Accordingly, we investigated the changing incidence of CAD and PAD respectively from 2006 to 
2015, using multiple data sources (GP consultations, hospital admissions and procedure level data) 
that are representative of the UK population. We also investigated the regional variations in the 
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incidence, trends in cardiovascular (CV) risk factors, statin use for secondary prevention, trends in 
annual major vascular event rates and mortality among patients with incident CAD and PAD 
respectively, from 2006 to 2015. 
Methods  
Data source  
Primary care records from general practitioners (GPs), including prescription data, caring for about 
9% of the UK population were obtained from the Clinical Practice Research Datalink (CPRD) covering 
the period between January 1st, 1986 to December 31st, 2016.18 Data from CPRD were linked to the 
hospital episode statistics (HES), which contains in-patient diagnostic and procedural records, and to 
the Office of National Statistics (ONS) for information on the date and cause of death.  
Study population  
People aged at least 18 years old with CAD or PAD were identified from CPRD using READ codes,  
from HES using International Classification of Diseases, tenth revision (ICD-10) codes and from Office 
of Population Censuses and Surveys Classification of Surgical Operations and Procedures  (OPCS) 
revision 4.6 for codes for coronary and peripheral revascularisations (Supplementary Appendix; 
Tables S6).  Patients with a prior diagnosis (before 1st January, 2006) of CAD or PAD (prevalent 
disease) were excluded for incidence calculation of CAD or PAD respectively. The incident diagnosis 
was defined as the first record of diagnosis in the primary care or hospital admission records. 
Incident cases (for both CAD and PAD) formed the base cohort for analyses of statin prescribing 
(Statin cohort) and HES linkage (Complications cohort) (Supplementary Figures S1 and S2)  
The investigation of statin use and its predictors was restricted to patients with incident CAD and 
PAD aged greater than 40 years who had complete follow-up data for at least one year from the 
date of diagnosis. Those transferring out of a CPRD participating GP practice or whose last collection 
date was within a year of diagnosis were excluded (Supplementary Figure S1 and S2). Patients who 
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could be linked to HES and ONS (~ 60% of patients in CPRD) were used to evaluate trends in the 
annual rates of major vascular events and mortality between 2006 and 2015. 
Patient characteristics  
Common co-morbidities were identified using CPRD READ codes. READ codes used in CPRD are the 
standard clinical terminology system used in General Practice across the UK.  READ codes gives 
detailed clinical coding of multiple patient features such as clinical signs, symptoms and 
observations; laboratory tests and results, medications and diagnoses.18 Socioeconomic status was 
reported using Index of Multiple Deprivation (IMD) 2015 quintiles, with quintile 1 being the least and 
quintile 5 the most deprived. Information on geographic region, ethnicity, other relevant clinical 
variables such as body mass index and baseline medications (prior to incident diagnosis) including 
antiplatelet therapy, statins, angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers (ACEI/ARB), beta-blockers, calcium channel blockers and other vasodilators were also 
obtained from the CPRD records. 
Outcomes  
The individual trends in the incidence of CAD and PAD between 2006 and 2015 were the primary 
outcomes of interest. The overall proportion of patients on a stable treatment regimen of statins, 
stratified by the type of vascular disease (CAD and PAD) and co-morbidities were described. A stable 
treatment regimen of statins was defined as prescriptions for more than 75% (273.75/365.25 days) 
of the first year after incident diagnosis. Finally, we present trends (from 2006 to 2015) in the annual 
age and sex adjusted event rates of complications including, myocardial infarction, stroke, 
hospitalisation for bleeding, CV hospitalisation (planned and unplanned), premature CV mortality 
(defined as death <75 years), CV mortality and all-cause mortality among patients with incident CAD 
and incident PAD.  The complication rates were analysed only for patients whose data from CPRD 







Baseline characteristics were expressed using mean ± standard deviation for continuous variables 
and percentages for categorical variables. Baseline characteristics were stratified by sex and three 
time periods of diagnosis (2006-07, 2010-11 & 2014-2015). We calculated sex and age specific (5 
year intervals) incidence rates per 100,000 person years for each year. For the denominator, the 
total person years in each year was calculated in 5 year age intervals. Standardised incidence rates 
were computed individually for CAD and PAD on the basis of 2013 European standard population 
distribution of age and sex.19 We employed Poisson regression models to estimate adjusted 
incidence rate ratios (IRR) and 95% confidence intervals (CI) for quantifying the change in the 
incidence rates between 2006 and 2015.   
The proportion of incident CAD and incident PAD patients on statins, stratified by baseline co-
morbidities were analysed. Logistic regression model was used to investigate the predictors of statin 
use (or non-use) after an incident diagnosis, separately for patients with incident CAD and patients 
with incident PAD. We adjusted the model for age, sex, year of diagnosis, and relevant co-
morbidities including, diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD), 
chronic obstructive pulmonary disease (COPD), depression, dementia, history of malignancy, chronic 
liver disease (CLD), and prior history of ischemic stroke; in addition to these, the model was also 
adjusted for prior history of PAD for incident CAD patients and prior history of CAD for incident PAD 
patients.  
The event rates of complications were defined as the annual rate of occurrence (per 100 person 
years) of the complications during the first year of follow up. Total follow-up was calculated from the 
time of incident CAD or PAD diagnosis in CPRD or HES and the date of the outcome (i.e. first event 
for each outcome of interest), death (when it is not the outcome), date of disenrollment in the 
practice or of the practice in CPRD, or the end of follow up (one year from the date of incident 
diagnosis). Rates were age and sex standardised to 2013 European Standard Population. For all the 
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complications, we computed adjusted IRR and 95% CI to estimate changes in the event rates over 
time (2006 to 2015), separately for incident CAD and incident PAD patients. We performed 
sensitivity analyses for event rates and mortality in incident PAD patients by excluding those with 
history of concomitant CAD (Please see Supplementary Appendix for details).  
Ethics approval 
The study was approved by the Independent Scientific Advisory Committee of the Medicine and 
Healthcare Products Regulatory Agency (MHRA) for database research (protocol number: 18_057R). 
The data are anonymous, and the requirement for informed consent was therefore waived 
Role of funding source 
The present work was funded by a research grant from Bayer. VS and JKQ had full access to all the 
data and all authors made the final decision to publish. We had two Bayer representatives that were 
engaged in the project: KB and JBB. Both representatives participated to the funding of the study. KB 
and JBB were not involved in the data analyses and the results interpretations. No Bayer drug was 
involved in the study limiting risk of potential conflict of interest. 
Results  
From 15.4 million patient records, 4,618,735 people who were alive on Jan 1, 2006 were identified 
of whom 184,814 had prevalent CAD and 52,667 had prevalent PAD (Supplementary Figures S1 and 
S2). Between 2006 and 2015, 160,376 incident cases of CAD (base-cohort for CAD) and 70,753 
incident cases of PAD (base-cohort for PAD) were identified. Using multiple data sources, compared 
to using primary care encounters only, we identified an additional 38,207 cases of incident CAD (25% 
increase) and 4,500 incident cases of PAD (7% increase) (Supplementary Figure S3).  
Incidence of CAD and PAD  
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Across the UK, there was no change in the age- and sex-standardised incidence of CAD between 
2006 and 2015 [443 per 100,000 person years in 2006 and 436 per 100,000 person years in 2015; 
adjusted IRR 0.98, 95% CI 0.96 - 1.00] (Figure 1 and Take home figure). Similarly, there was no 
change in the crude incidence for CAD from 439 per 100,000 person years in 2006 to 450 per 
100,000 person years in 2015 (IRR 1.02, 95% CI 1.00 - 1.05) (Figure 2). The age-standardised 
incidence of CAD was higher amongst men (650 per 100,000 person years) than women (370 per 
100,000 person years) (Supplementary Figures S4 and S5). The trends in standardised incidence of 
CAD among men and women remained relatively stable from 2006 to 2015 (adjusted IRR for men 
1.00, 95% CI 0.96 – 1.03; adjusted IRR for women 0.97, 95% CI 0.93 – 1.00) (Supplementary Figures 
S4 and S5). In keeping with the overall trend for CAD (which included chronic ischemic heart disease 
and AMI), the age- and sex-adjusted incidence rates for AMI were similar in 2006 and 2015 (adjusted 
IRR 0.99, 95% CI 0.95 – 1.03). We observed a transient increase in the age- and sex-standardised 
incidence of CAD peaking in 2008, similar to an earlier report on AMI in the UK (please see 
supplementary appendix for details).11 
There was a 15% decline in the age- and sex-standardised incidence of PAD from 236 per 100,000 
person years in 2006 to 202 per 100,000 person years in 2015 (adjusted IRR 0.85, 95% CI 0.82 - 0.88) 
(Figure 1 and Take home figure). In line with the standardised rates, there was 10% decline in the 
crude incidence of PAD – falling from 234 per 100,000 person years in 2006 to 211 per 100,000 
person years in 2015 (IRR 0.90, 95% CI 0.87 - 0.93) (Figure 2). The decrease in the standardised 
incidence of PAD over time was consistent across most of the age groups. Age-standardised PAD 
incidence was higher in men (300 per 100,000 person years) than women (156 per 100,000 person 
years). Reductions in the age-standardised incidence of PAD in women from 2006 to 2015 (adjusted 
IRR for women 0.86, 95% CI 0.81 – 0.91) exceeded those for men (adjusted IRR for men 0.93, 95% CI 
0.89 – 0.97) (Supplementary Figures S4 and S5). 
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Regional variations in the standardised incidence of CAD in England which were apparent in 2006, 
particularly the difference between the north and south, were lower in 2015 (Supplementary Figure 
S6). There was an overall decline in the age and sex standardised incidence of PAD, which was 
substantial in some regions (e.g.:- >30% in north-west and north-east England) (Supplementary 
Figure S7). 
Patient characteristics stratified by sex and time period  
The mean age at diagnosis for CAD and PAD was similar and did not change between 2006 and 2015 
(Tables 1 and 2). Patients diagnosed in more recent years were more likely to be obese, have DM, 
CKD, dyslipidaemia and a history of cancer. Women were slightly older and had more co-morbidities 
than men. The use of statins and ACE inhibitors (for primary prevention) prior to an incident 
diagnosis increased substantially from 2006 to 2015 in both CAD and PAD (Table 1 and Table 2). 
Predictors of statin non-use for secondary prevention 
We included 121,011 incident cases of CAD and 49,426 incident cases of PAD (Statin cohort) 
(Supplementary Figures S1 and S2). The proportion of incident cases of CAD and PAD who qualified 
as receiving a stable statin treatment regimen were 66% and 55% respectively. Notably, over 40% of 
women and 50% of elderly (age > 70 years) with established ASCVD (CAD and PAD), were not on a 
stable statin regimen (Table 3 and Supplementary Table S3). In a multivariable logistic regression 
model, for patients with CAD, failure was associated with female sex (odds ratio [OR] 0.67, 95% CI 
0.65 - 0.69), heart failure (OR 0.73, 95% CI 0.69 – 0.78), age >70 years (OR 0.87, 95% CI 0.84 - 0.90), 
COPD (OR 0.82, 95% CI 0.78 – 0.86) and depression (OR 0.86, 95% CI 0.81 – 0.90) and was similar for 
PAD (Figure 3). Statin uptake did not increase significantly between 2006 and 2015 (Supplementary 
appendix Figure S8). 
Trends in the annual event rates of major vascular events and mortality from 2006 to 2015 
We included 114,807 incident cases of CAD and 45,503 incident cases of PAD (those eligible for HES-
ONS linkage; Complication cohort).  The overall annual age- and sex-standardised rates for MI were 
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higher for CAD than for PAD but the reverse was true for ischemic stroke (Table 4). The age- and sex-
standardised annual CV mortality was similar for CAD and PAD. However all-cause mortality was 
higher for PAD (9.2 per 100 person years, 95% CI 9.0-9.5) compared to incident CAD (8.2 per 100 
person years, 95% CI 8.1-8.4). Age-adjusted rates of MI and bleeding requiring hospitalisation were 
higher in men than in women for both CAD and PAD, whereas the rate of ischemic stroke for those 
with incident CAD group was higher in women (Table 4 and Supplementary Table S4). Morbidity and 
mortality were similar for patients with PAD whether or not they had CAD (Supplementary Table S4). 
The annual crude incidence rates of amputation and acute limb ischemia in the overall PAD 
population were 2.2 (95 % CI, 2.0-2.4) and 0.6 (95 % CI, 0.5-0.7) per 100 person years of follow up 
respectively (Supplementary Table S5).  
Comparing 2006 vs 2015, the annual age- and sex-adjusted rate of MI fell by 48% in those with 
incident CAD (adjusted IRR 0.52, 95% CI 0.43 - 0.63) and 56% in those with incident PAD (adjusted 
IRR 0.44, 95% CI 0.32 – 0.61) (Figure 4). The greatest reduction in the annual event rates of stroke 
were observed in incident PAD patients [PAD: adjusted IRR 0.63 (0.45 - 0.89); CAD adjusted IRR 0.84 
(0.66 - 1.07)]. Between 2006 and 2015, there were no significant changes in the annual crude and 
adjusted rates of lower extremity amputations [crude incidence rate ratio (IRR): 1.2, 95% CI, 0.9 - 
1.7; adjusted IRR: 1.2, 95% CI 0.9 – 1.7] and acute limb ischemia [crude IRR: 1.1, 95% CI, 0.3 - 3.3; 
adjusted IRR: 1.2, 95% CI 0.4 - 3.0] (Supplementary Table S5).  A marked decline in CV mortality 
(43%) was observed amongst cases of incident CAD from 2006 to 2015 (adjusted IRR 0.57, 95% CI 
0.50 – 0.64) which was less obvious amongst cases of incident PAD (adjusted IRR 0.86, 95% CI 0.70 – 
1.00) (Figure 4), with or without concomitant CAD (Supplementary Figure S10). The rate of all-cause 
mortality fell amongst cases of incident CAD but rose amongst cases of PAD even after adjusting for 




This study of a large nationally representative population in the UK over one decade provides vital 
insights into the trends in incidence, risk factors, statin use, major vascular complications and 
mortality of two important clinical spectrums of ASCVD – CAD and PAD.  
In contrast to previous studies that have reported a decline until 2010, the incidence of CAD in 
models standardised for age and sex, in our study, has remained relatively stable between 2006 and 
2015.2,11 The absence of a decline in CAD incidence in our study versus the findings of previous 
studies could have been caused by myriad reasons. Whilst improvements in primary prevention 
measures were expected to decrease the incidence of CAD16, offsetting trends such as an increase in 
the prevalence of obesity, dyslipidaemia, diabetes and CKD may have attenuated the decline. 
Secondly, previous studies on the incidence of AMI included patients with prior history of chronic 
ischemic heart disease.11,13,20 As result of this, some of those patients could have been on CV 
prevention medications, which in turn may have contributed to the decline in the incidence rates of 
AMI. Finally, there could have been an increase in the detection of non-ST elevation MI (NSTEMI), 
attributable to the introduction of high sensitivity troponin (hsTnT) as a diagnostic marker. The 
European Society Cardiology Study Group on Biomarkers in Cardiology recommended the routine 
use of hsTnT as a diagnostic biomarker for AMI in 2012,20 possibly leading to additional identification 
of cases since. Data from the other European countries and the United States also have reported an 
increase in the incidence of NSTEMI.22–25   
Contrary to the trends in CAD, there was a 15% reduction in the standardised incidence of PAD 
during the study period. The fall in the incidence rates of PAD could be due to policy measures 
incorporating primary prevention of ASCVD. Moreover, a significant proportion (30 - 50%) of PAD 
patients have CAD prior to their diagnosis26, which could have led to an increased uptake of CV 
medications. 
There was a notable shift in the co-morbidity burden over the last decade, especially among patients 
with incident PAD. Patients diagnosed with incident PAD in the more recent years (2014-15) were 
13 
 
sicker, with a significantly higher proportion of patients with co-morbidities including obesity, DM, 
HLD, CKD, COPD and malignancy, compared to those diagnosed in 2006-07. In the UK National 
Health Service (NHS), the Quality and Outcomes Framework (QOF) introduced a pay for performance 
program in 2004. 27 Further changes were brought to the QOF reporting system in 2008, including 
the introduction of new indicators such as COPD and smoking cessation. 28 Given our study time 
frame begins in 2006, the 2004 QOF changes would have been assimilated in the data analysed. The 
rising trends in the CV and non-CV co-morbidities from 2006-07 to 2010-11 observed in our analyses 
may, in part, correspond to the differences in coding practices resulting from the QOF changes in 
2008. However, changes observed in the later part of the study period (from 2010-11 to 2014-15) 
are unlikely to be related to coding practice changes. 
Our findings suggest, in spite of consistent evidence from multiple RCTs that statins reduce recurrent 
CV events in patients with established ASCVD, statins remain underutilized in clinical practice in the 
UK.  A substantial segment of incident CAD (~ 1 out of every 3 CAD patients) and incident PAD (~ 1 
out of every 2 PAD patients) patients were not receiving long term statin therapy. Our analyses also 
revealed that in addition to statins, dual and single antiplatelet therapy was also less often 
prescribed for those with incident PAD than those with CAD (Supplementary Figure S9). These 
findings are in line with the results of other large studies such as the PURE study and the SHARE 
study, where 30-40% of patients with established ASCVD in the developed countries were not 
prescribed with statin.29–31 We observed the phenomenon of “risk treatment paradox” 32 in our study 
population i.e., ASCVD patients at higher risk (elderly, female, CHF, COPD and depression) for CV 
outcomes were less likely to have been prescribed persistent statin therapy by their physicians. 
Meta-analysis of individual data of 174,000 patients by the Cholesterol Treatment Trialists’ (CTT) 
collaboration, showed significant reductions in recurrent CV events with statin among elderly 
patients with pre-existing vascular disease.33 However, we observed an inverse relationship between 
treatment propensity and age with regard to statins. Among all the variables, female sex was the 
most significant predictor to have negatively influenced physician prescribing pattern with statins, 
14 
 
after accounting for important confounders. Despite compelling evidence of the benefits of statin in 
women, 34 the reasons for the barriers in clinical practice remains unclear. Women may be more 
prone to statin induced myalgias, which could have led to more early discontinuations.35 It has been 
shown that intense media publicity of exaggerated side effects of statins may have had a negative 
impact on continuation of statins, with more profound effects on women.36,37 Our findings shine a 
spotlight on the necessity to highlight sex specific disparities in the utilisation of statins in clinical 
practice to patients and physicians, and the imperative to implement additional sex specific 
strategies to improve CV outcomes for women.  
Previous studies have demonstrated an increased bleeding risk after MI and PCI in women than 
men.38,39 Conversely, we observed a higher age-adjusted bleeding rates requiring hospitalisation in 
men than women. This could be related to the higher annual age adjusted event rates of MI and 
subsequent use of DAPT during follow up in men (Table 4 and Supplementary Figure S9). While, 
these can partly explain the increased bleeding rates among men compared to women, unmeasured 
confounders (such as undisclosed bleeding risk etc.) might be a plausible reason for this observed 
difference. A single reason for this disparity is not clear from this data.  
The trends in outcomes from 2006 to 2015 suggest that the reduction in the annual CV event rates 
and CV mortality in patients with incident CAD outpaced their PAD counterparts (even after 
excluding patients with concomitant CAD) (Figure 4 and Supplementary Figures S10-S13). The 
significant decline in recurrent CV events, recurrent CV hospitalisation and CV mortality among 
patients with incident CAD in the latter part of our study could be a consequence of improvements 
in treatment, particularly the health care policy measures related to early revascularisation in AMI. 
Furthermore, changes in guidelines and clinical practice, including the duration of antiplatelet 
therapy and the introduction of potent newer antiplatelet therapy agents (prasugrel and ticagrelor) 
could have influenced the adjusted incident rate ratio (2015 vs 2006) of CV outcomes (both ischemic 
events and bleeding).40–43 However, this could also be related to an increase in the frequency of 
15 
 
detecting smaller infarcts with less severity after the widespread utilisation of hsTnT. Conversely, in 
patients with incident PAD, there was no significant reduction in CV mortality over time. There are 
several potential explanations for this. Although the prevalence of smoking in the overall UK 
population has declined, contributing to the falling incidence of PAD, the prevalence of smoking 
amongst those who develop PAD has not changed over time. In addition to increasing the risk of 
incident PAD, cigarette smoking reduces exercise capacity and increases CV mortality among 
patients with prevalent PAD.44 In the UK, a primary care service network was established for 
evaluation of symptomatic PAD in primary care in 2009. However, the onset of symptoms in PAD 
indicates advanced systemic atherosclerosis and the effect of disease modifying CV medications 
might be less than what is observed in patients with CAD alone. A significant proportion of patients 
with PAD have established atherosclerosis in other vascular beds which could have an additive or 
multiplicative effect on CV mortality. However, sensitivity analyses of incident PAD patients 
excluding those with concomitant CAD demonstrated results comparable to the overall incident PAD 
patients (Supplementary Figure S10).  
Strengths and limitations 
Unlike previous studies, we included the entire spectrum of patients with CAD from all possible 
clinical encounters within the UK health system including chronic ischemic heart disease from GP 
encounters (READ codes), hospitalisations for AMI (HES codes) and from procedural records for 
coronary revascularisations (OPCS 4.6 codes). By this process, we identified an additional 38,207 
incident CAD patients, a 25% increase (Supplementary Figure S3), utilizing multiple nationally 
representative data sources in comparison to conventional case ascertainment using one data 
source only. 
Our study has several strengths but some limitations. While we hypothesise that the introduction of 
hsTnT could have led to an increase in the incidence of CAD after 2012 (due to an increase in NSTEMI 
cases), we were not able to perform a stratified analyses by AMI type, as ICD10 subcategory codes, 
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do not reliably distinguish AMI type.45 CPRD captures medications that are prescribed to patients. 
The fact that the patient received a prescription for a medication does not ensure that the patient 
actually filled or even took the medication. In addition, over-the-counter medication use or 
medications administered during hospitalisations were not captured. Our analyses was also 
restricted to the use of statin and not the dosage of statins (high potency statins) which is clinically 
relevant with the recent changes in guidelines. Only 60% of the CPRD patients eligible for HES and 
ONS linkage were included for the vascular events and mortality analyses. Another limitation of 
research using electronic health records includes the potential for misclassification of diseases and 
of the outcomes. Wherever possible, definitions and algorithms that have been validated in these 
data sources were preferentially used to identify both the diseases of interest as well as 
complications. 46,47 
Conclusion  
In conclusion, the standardised incidence of CAD appears stable but mortality rates are falling, 
whereas the standardised incidence of PAD is falling but mortality rates are not. The stable incidence 
of CAD, despite primary prevention measures, remains an important concern for healthcare policy 
planning for an aging population. In the general population, statin use for secondary prevention 
remains suboptimal and the uptake has not increased in the past decade, necessitating measures to 
address this gap. Our findings also highlight the importance of early identification of PAD so that 
disease modifying interventions (e.g., smoking cessation and statins) to improve CV outcomes can be 
implemented in a timely fashion.   
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Figure legends  
Figure 1 A) Age and sex standardised incidence rates (per 100,000 person years) of CAD in the UK 
in 2006 vs 2015; 1 B) Age and sex standardised incidence rates (per 100,000 person years) of PAD 
in the UK in 2006 vs 2015 
** IRR: incidence rate ratio adjusted for age and sex; CAD: coronary artery disease; PAD: peripheral artery 
disease 
** Figure 1A shows stable standardised incidence rates of CAD between 2006 and 2015; Figure 1B shows a 
decline in the standardised incidence of PAD between 2006 and 2015 
Figure 2 A) Number of cases stratified by age group (per total person years of follow in each age 
category) of CAD in the UK in 2006 vs 2015; 2 B) Number of cases stratified by age group (per total 
person years of follow in each age category) of PAD in the UK in 2006 vs 2015 
** IRR: incidence rate ratio adjusted for age and sex; CAD: coronary artery disease; PAD: peripheral artery 
disease 
** Figure 2A shows no significant change in the crude incidence of CAD between 2006 and 2015; Figure 2B 
shows a decline in the crude incidence of PAD between 2006 and 2015 
Figure 3; Predictors of statin use for secondary prevention among patients with incident CAD and 
incident PAD 
**Statin analyses was performed individually for incident CAD and incident PAD patients. The model was 
adjusted for age, sex, and relevant co-morbidities including, diabetes mellitus, hypertension, chronic kidney 
disease, chronic obstructive pulmonary disease, depression, dementia, history of malignancy, chronic liver 
disease, and prior history of stroke. In addition to these, the model was also adjusted for prior history of PAD 
for incident CAD patients and prior history of CAD for incident PAD patients. 
Figure 4; Trends in the annual age and sex adjusted event rates of major vascular events, bleeding, 
hospitalisation and mortality among patients with incident CAD and incident PAD in 2006 vs 2015 
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** MI: Myocardial infarction, CV hospitalisation: cardiovascular hospitalisation (planned and unplanned), 
Premature CV death: Death <75 years of age due to cardiovascular cause, CV death: Death due to 
cardiovascular cause 
Take home figure: Temporal trends in the standardised incidence and CV mortality of CAD and 
PAD in the UK, 2006-2015 
 
